FDA Brief

Warning letters Food

FDA warning letter to

Everything Health LLC

High riskIssued May 24, 2021Posted Jun 8, 2021Center for Food Safety and Applied Nutrition

Everything Health sold CoronaBox as an unapproved COVID-19 drug, FDA and FTC say.

What happened

FDA reviewed the website on February 23, 2021, and FTC reviewed it on May 11, 2021; FDA also reviewed linked social media pages that directed consumers to the site. FDA found CoronaBox offered for sale with claims that it could mitigate, prevent, treat, diagnose, or cure COVID-19. FDA called it an unapproved new drug (a drug sold without FDA approval) and a misbranded drug (labeled or promoted with false or misleading claims).

What FDA found

  1. The company sold CoronaBox as an unapproved new drug (a drug sold without FDA approval) for COVID-19.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The company misbranded CoronaBox by promoting it for COVID-19 uses that FDA has not approved.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company introduced or delivered the product into interstate commerce despite these violations.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that CoronaBox can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA asks the company to take immediate action to stop selling unapproved COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CFSAN@fda.hhs.gov with the steps taken and documents showing prevention of recurrence. FTC separately asks for an email to Richard Cleland at rcleland@ftc.gov within 48 hours describing actions taken.

Who should pay attention

  • online sellers of supplement bundles
  • companies making COVID-19 health claims
  • social media influencers promoting health products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk